iifl-logo-icon 1

Kobo Biotech Ltd Share Price

4.01
(-3.37%)
Jul 22, 2024|01:51:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open4.15
  • Day's High4.29
  • 52 Wk High6.01
  • Prev. Close4.15
  • Day's Low3.98
  • 52 Wk Low2.05
  • Turnover (lac)0.38
  • P/E0
  • Face Value10
  • Book Value-55.78
  • EPS0
  • Mkt. Cap (Cr.)9.55
  • Div. Yield0
No Records Found

Kobo Biotech Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

4.15

Prev. Close

4.15

Turnover(Lac.)

0.38

Day's High

4.29

Day's Low

3.98

52 Week's High

6.01

52 Week's Low

2.05

Book Value

-55.78

Face Value

10

Mkt Cap (₹ Cr.)

9.55

P/E

0

EPS

0

Divi. Yield

0

Kobo Biotech Ltd Corporate Action

23 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

9 Sep 2023

12:00 AM

AGM

Announcement Date: 09 Sep, 2023

arrow

Kobo Biotech Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Kobo Biotech Ltd SHAREHOLDING SNAPSHOT

22 Jul, 2024|02:12 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 44.94%

Foreign: 0.00%

Indian: 44.94%

Non-Promoter- 0.67%

Institutions: 0.66%

Non-Institutions: 54.38%

Custodian: 0.00%

Share Price

Kobo Biotech Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

23.83

23.83

23.83

23.83

Preference Capital

0

0

0

0

Reserves

-151.81

-146.25

-131.03

-111.8

Net Worth

-127.98

-122.42

-107.2

-87.97

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

0

0

0

0

yoy growth (%)

0

0

0

-100

Raw materials

0

0

0

0

As % of sales

0

0

0

0

Employee costs

-1.39

-1.79

-2.42

-3.11

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

-19.23

-21

-23.92

-19.23

Depreciation

-5.63

-5.87

-6.44

-6.78

Tax paid

0

0

0

0

Working capital

-3.83

-4.65

-3.11

7.09

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

0

0

0

-100

Op profit growth

305.58

-77.23

-25.31

-184.17

EBIT growth

28.46

-30.7

95.07

131.74

Net profit growth

-8.44

-12.19

24.35

16.88

View Ratios
Particulars (Rupees in Crores.)Mar-2014Mar-2013Mar-2012Mar-2011

Gross Sales

103.19

403.66

287.26

162.11

Excise Duty

0

0

0

0

Net Sales

103.19

403.66

287.26

162.11

Other Operating Income

0

0

0

0

Other Income

0.25

0.37

0.23

0.25

Kobo Biotech Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.45

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,520.1

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.15

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.6

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,639.05

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Kobo Biotech Ltd

Management

Register Office

Registrar Office

Chairman (Non-Executive)

Ajit Kamath

Non-Exec & Non-Independent Dir

Rajendra Kaimal

Company Sec. & Compli. Officer

Jignesh Patel

Non-Exec. & Independent Dir.

Sunil Pitroda

Non-Exec. & Independent Dir.

Abhishek Buddhadev

Non-Exec. & Independent Dir.

Urja Shah

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992. Effective 19th October, 2020, the Companys name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited. The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The companys 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US. XTP shall be the technical supervisor for the transfer of technology, while SMEC shall supply the technical knowhow.The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA, MMAE, DEA, EEAA and Aralydes.The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Techno
Read More

Company FAQs

What is the Kobo Biotech Ltd share price today?

Down Arrow

The Kobo Biotech Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹4.01 today.

What is the Market Cap of Kobo Biotech Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kobo Biotech Ltd is ₹9.55 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Kobo Biotech Ltd?

Down Arrow

The PE and PB ratios of Kobo Biotech Ltd is 0 and -0.07 as of 22 Jul ‘24

What is the 52 Week High and Low of Kobo Biotech Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Kobo Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kobo Biotech Ltd is ₹2.05 and ₹6.01 as of 22 Jul ‘24

What is the CAGR of Kobo Biotech Ltd?

Down Arrow

Kobo Biotech Ltd's CAGR for 5 Years at 9.80%, 3 Years at -15.83%, 1 Year at 79.65%, 6 Month at 16.57%, 3 Month at 6.41% and 1 Month at -2.81%.

What is the shareholding pattern of Kobo Biotech Ltd?

Down Arrow

The shareholding pattern of Kobo Biotech Ltd is as follows:
Promoters - 44.95 %
Institutions - 0.66 %
Public - 54.39 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.